sujets spéciaux
Cannabidiol (CBD)
Références
1.Bonn-Miller MO, Loflin MJE, Thomas BF, et al: Labeling accuracy of cannabidiol extracts sold online.JAMA318(17):1708-1709, 2017. doi:10.1001/jama.2017.11909 2.Szaflarski JP, Bebin EM, Comi AM, et al: Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: Expanded access program results.Epilepsia59(8):1540-1548, 2018. doi:10.1111/epi.14477 3.Szaflarski JP, Bebin EM, Cutter G, et al: Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study.Epilepsy Behav87:131-136, 2018. doi:10.1016/j.yebeh.2018.07.020 4.Mucke M, Phillips T, Radbruch L, Petzke F, Hauser W: Cannabis-based medicines for chronic neuropathic pain in adults.Cochrane Database Syst Rev3(3):CD012182, 2018. Publié le 7 mars 2018. doi:10.1002/14651858.CD012182.pub2 5.Balachandran P, Elsohly M, Hill KP: Cannabidiol interactions with medications, illicit substances, and alcohol: a comprehensive review.J Gen Intern Med36(7):2074-2084, 2021. doi:10.1007/s11606-020-06504-8 